Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
Tail-anchoring of Proteins in the ER Membrane01:45

Tail-anchoring of Proteins in the ER Membrane

3.9K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impending Abdominal Aortic Aneurysm Rupture Associated With IgG4-RD.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Biologics reduced infections in ankylosing spondylitis and psoriatic arthritis under immunosuppressants.

Journal of the Chinese Medical Association : JCMA·2026
Same author

High Burden of Coinfection in Systemic Lupus Erythematosus with Bronchoalveolar Lavage Confirmed Pneumocystis jirovecii Pneumonia: A Single-Center Retrospective Study.

Modern rheumatology·2026
Same author

Aortitis Due to Large-Vessel Vasculitis.

The New England journal of medicine·2026
Same author

Cumulative defined daily doses enable objective assessment of treatment intensity and outcome prediction in immunoglobulin G4-related disease and its subtypes.

Rheumatology (Oxford, England)·2026
Same author

Amorphous calcium carbonate supplementation and bone outcomes in rheumatoid arthritis: A prospective cohort study.

Medicine·2026

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.9K

Semaphorin 3A in Ankylosing Spondylitis.

Hsien-Tzung Liao1, Yuh-Feng Lin2, Chung-Tei Chou3

  • 1Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|July 25, 2017
PubMed
Summary

Serum semaphorin 3A (Sema 3A) is elevated in ankylosing spondylitis (AS) patients and shows promise as a biomarker. Higher Sema 3A levels correlate with disease activity and extra-articular manifestations, aiding in monitoring treatment effectiveness.

Keywords:
Ankylosing spondylitisBiomarkerBone remodelingOsteoimmunologySemaphorin 3A

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K

Related Experiment Videos

Last Updated: Feb 26, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.9K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K

Area of Science:

  • Immunology
  • Rheumatology
  • Biochemistry

Background:

  • Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton.
  • Understanding novel biomarkers for AS disease activity and extra-articular manifestations is crucial for effective management.

Purpose of the Study:

  • To investigate serum semaphorin 3A (Sema 3A) levels in patients with ankylosing spondylitis (AS).
  • To evaluate the potential of Sema 3A as a biomarker for disease activity, functional status, and extra-articular involvement in AS.

Main Methods:

  • Serum Sema 3A levels were quantified in 46 AS patients and 30 healthy controls (HCs).
  • Demographic data, disease activity (BASDAI, BASFI, BAS-G), human leukocyte antigen-B27 (HLA-B27), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were assessed.
  • Correlations between Sema 3A levels and clinical parameters, including uveitis and interstitial lung disease, were analyzed.

Main Results:

  • Serum Sema 3A levels were significantly higher in AS patients compared to HCs (p=0.013).
  • Sema 3A demonstrated superior predictive value for high disease activity (BASDAI > 4) compared to ESR and CRP.
  • Elevated Sema 3A correlated with uveitis, reduced Schöber's test results, and interstitial lung disease.

Conclusions:

  • Serum Sema 3A is elevated in AS and serves as a potential biomarker for disease activity and extra-articular manifestations.
  • Sema 3A shows promise in monitoring disease activity and functional status during anti-tumor necrosis factor (anti-TNF) therapy.
  • Further research is warranted to establish Sema 3A as a predictor for extra-articular presentations in AS.